Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination, in Patients With Advanced Solid/Metastatic Tumours

Next Previous
Search
Trial Profile

An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination, in Patients With Advanced Solid/Metastatic Tumours

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abiraterone acetate (Primary) ; Atezolizumab (Primary) ; Darolutamide (Primary) ; Enzalutamide (Primary) ; Inobrodib (Primary) ; Olaparib (Primary) ; Prednisolone; Prednisone
  • Indications Advanced breast cancer; Male breast cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors CellCentric

Most Recent Events

  • 30 Apr 2025 Planned End Date changed from 1 Dec 2024 to 1 Aug 2025.
  • 30 Apr 2025 Planned primary completion date changed from 1 Dec 2024 to 1 Aug 2025.
  • 30 Apr 2025 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top